Displaying 1–25 of 270 results for Paul Thomas, Senior Editor
In this interview, Wessels talks with PharmaManufacturing.com Senior Editor Paul Thomas about why sustainability matters, and how sustainable practices can become part of a drug manufacturers genetic makeup.
By better combining and interpreting readily available data, biomanufacturing experts are gaining better control of fermentation and other processes, says Sartorius Roland Bienert
An interview with Thomas Schilling on the companys Green IT initiative.
Middle managers in pharma today have a tough, thankless jobbut someones got to do it, and many do it well.
Organizations with built-in risk management frameworks allow middle managers to thrive, says Scott Chizzo, Maxiom Groups president and chief consultant, in this exclusive interview.
If the serial acquirers dont kill us, theyll make us stronger.
Know when youre on shaky ground, and then respond promptly and thoroughly to FDAs requests, says J&J Janssens Patti Gupta.
If Ashton Kutcher were in pharma, hed be on LinkedIn.
The annual spring tradeshow has reenergized itself by building a year-round online presence.
Theres nothing like a good tale of frugality to make your day.
Reports of the demise of radio frequency identification as a breakthrough supply chain technology have been greatly exaggerated.
Can standardization and innovation coexist?
With real-time, wireless and other new monitoring technologies, pharma gains better control of temperature, pressure, humidity, and more.
For CEOs, maybe therapy comes with the territory.
Theres no good way to deliver bad news, but that doesnt mean it should be hidden or glossed over.
As paradigms shift, we also need paradigm expansion.
A Milwaukee newspaper reminds an industry of its flaws.
Probabilistic rather than deterministic modeling is essential, says Quintiles Davis Walp.
Makers of drugs for lethal injection face pressure to spurn U.S. prisons.
Communities can partner with manufacturers, but they cant apply pressure.
Its time to make counterfeiting less economically tantalizing.
If not, maybe greed can help overcome manufacturings PR problem with young professionals.
"OUS" companies are enjoying the U.S. market, and creating a few jobs along the way.
Salary does not dictate motivation and performance.
To survive, Steven Burrill tells Big Pharma, ignore the gravel in the road and embrace the disruption.